Friday, June 19, 2015

Gilead suffers IP reverse in China

China has rejected a patent application of Gilead, related to a precursor drug to Sovaldi

Reuters noted:

Officials at China's State Intellectual Property Office did not confirm the decision when contacted by Reuters, but a notice posted on the body's website said Gilead's application for "nucleoside phosphramidates", a kind of prodrug, had recently been rejected.

China's move follows a decision by India's patent office in January to reject Gilead's patent application for Sovaldi, finding it was not inventive enough. Gilead is appealing the ruling.



Post a Comment

<< Home